Vaccines for Lymphomas

Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against lymphomas and guarantee the finest results for our customers all over the world.

Lymphoma is a group of hematological cancers that develop from lymphocytes, a type of white blood cell. Lymphoid malignancies represent the largest class of hematologic cancers and are highly heterogeneous in their histologic characteristics and clinical behavior. Signs and symptoms may include fever, swollen lymph nodes, excessive dribbling, unexpected weight loss, and constant tiredness. Treatment may involve some combination of chemotherapy, radiotherapy, targeted therapies, and surgery.

Types of Lymphomas

There are dozens of subtypes of lymphomas. The two main categories of lymphomas are Hodgkin's lymphomas (HL) and the non-Hodgkin lymphomas (NHL).

Hodgkin’s lymphoma (HL): Risk factors for Hodgkin lymphoma include infection with Epstein–Barr virus and a history of the disease in the family.
Non-Hodgkin’s lymphomas (NHL): About 90% of lymphomas are non-Hodgkin lymphomas. Risk factors for common types of non-Hodgkin lymphomas include autoimmune diseases, HIV/AIDS, infection with human T-lymphotropic virus, immunosuppressant medications, and some pesticides. Eating large amounts of red meat and tobacco smoking may also increase the risk.

Our Therapeutic Vaccine Platforms for Lymphomas

Creative Biolabs are developing several types of therapeutic vaccines for the active immunotherapy of lymphoma.

Vaccines that targeting the clonal, tumor-specific immunoglobulin (idiotype) expressed by malignant B cells: Idiotype protein is the only fully characterized antigen available as a target for active vaccination. Idiotype vaccines have reached an advanced stage of development.
Whole tumor cells-based vaccines: including gene-modified tumor cells and heat shock protein-peptide complexes. Heat shock protein-peptide complexes presumably contain mixtures of uncharacterized tumor antigens and are being studied in preclinical models for various types of cancers, including low grade lymphomas.

Immune effectors recruited by active vaccination against idiotype. Idiotype vaccination has the potential to induce anti-idiotype antibodies and CD4+ and CD8+ T cells, recognizing idiotype peptides in association with major histocompatibility complex (MHC) molecules on the cell surface.

Fig.1 Immune effectors recruited by active vaccination against idiotype.

Idiotype protein vaccines are the mainstay of lymphoma vaccine research, but several other promising approaches may soon be entering the clinic, including vaccination with GM-CSF gene-transduced tumor cells. This strategy has robust activity in a murine lymphoma model and is undergoing phase I testing in multiple myeloma. Another related gene therapy approach is immunization with tumor cells infected with CD40 ligand encoding adenovirus, in which encouraging results have been obtained in chronic lymphocytic leukemia.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the vaccine development for lymphomas. If you are interested in our services, please contact us for more details.

Reference

Montross, S. (2006). “Vaccine therapies for non-Hodgkin's lymphomas.” Cancer Treat Res 131: 283-315.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.